Prevatex Shareholder Newsletter – December 2022

Click through to view the December Shareholder Newsletter.

Carriage of Prevotella by pregnant mothers protects against food allergy in the child at one year of age – data from the Barwon Infant Study

Click through to view the publications.

Increased abundance of Prevotella in children at one year associated with reduced behavioural problems at 2 years of age – data from the Barwon Infant Study

Click through to view publications.

Abundance of Prevotella in the gut microbiota is associated with reduced allergy – data from other studies

Click through to view the publications.

The abundance of Prevotella in the gut microbiota is associated with improved cardio-metabolic health – data from large population-based studies

Click through to view the publications.

Prevatex Shareholder Newsletter – April 2022

Click through to view the April Shareholder Newsletter.

Prevatex has signed a supply and licence agreement with Ipromea

Click through to view the details of this important commercial milestone.

Prevatex has signed a supply agreement with Probiotics Australia

Click through to view the details of this important commercial milestone.

Prevatex Shareholder Newsletter – November 2021

Click through to view the November Shareholder Newsletter.

Award for Prevatex’s scientific founder

Professor Peter Vuillermin has been awarded The Rue Wright Memorial Award of the The Royal Australasian College of Physicians (RACP) for 2019.